A screen for transcription factor targets of glycogen synthase kinase-3 highlights an inverse correlation of NFκB and androgen receptor signaling in prostate cancer

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8173-8187

  Campa, Victor M ^a,c   Baltziskueta, Eder ^a   Bengoa Vergniory, Nora ^a   Gorroño Etxebarria, Irantzu ^a   Wesolowski, Radoslaw ^a   Waxman, Jonathan ^b   Kypta, Robert M ^a,b  

^a CIC BIOGUNE   (Spain)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Androgen receptor; Glycogen synthase kinase 3; NF B transcription factor; Prostate cancer; Wnt signaling

Indexed keywords

6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; ANDROGEN RECEPTOR; DNA; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR RELB; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3 BETA; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DNA BINDING; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN TISSUE; MALE; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN FUNCTION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 84907969959     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2303     Document Type: Article

References (63)

1. Darrington RS, Campa VM, Walker MM, Bengoa-Vergniory N, Gorrono-Etxebarria I, Uysal-Onganer P, Kawano Y, Waxman J and Kypta RM. Distinct expression and activity of GSK-3alpha and GSK-3beta in prostate cancer. Int J Cancer. 2012; 131(6):E872-883.
2. Li R, Erdamar S, Dai H, Sayeeduddin M, Frolov A, Wheeler TM and Ayala GE. Cytoplasmic accumulation of glycogen synthase kinase-3beta is associated with aggressive clinicopathological features in human prostate cancer. Anticancer Res. 2009; 29(6):2077-2081.
3. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M and Martelli AM. Multifaceted roles of GSK-3 and Wnt/beta-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention. Leukemia. 2014; 28(1):15-33.
4. Mazor M, Kawano Y, Zhu H, Waxman J and Kypta RM. Inhibition of glycogen synthase kinase-3 represses androgen receptor activity and prostate cancer cell growth. Oncogene. 2004; 23(47):7882-7892.
5. Schutz SV, Schrader AJ, Zengerling F, Genze F, Cronauer MV and Schrader M. Inhibition of glycogen synthase kinase-3beta counteracts ligand-independent activity of the androgen receptor in castration resistant prostate cancer. PLoS One. 2011; 6(9):e25341.
6. Zhu Q, Yang J, Han S, Liu J, Holzbeierlein J, Thrasher JB and Li B. Suppression of glycogen synthase kinase 3 activity reduces tumor growth of prostate cancer in vivo. Prostate. 2011; 71(8):835-845.
7. Chen Y, Sawyers CL and Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008; 8(4):440-448.
8. Gioeli D and Paschal BM. Post-translational modification of the androgen receptor. Mol Cell Endocrinol. 2012; 352(1-2):70-78.
9. Liao X, Thrasher JB, Holzbeierlein J, Stanley S and Li B. Glycogen synthase kinase-3beta activity is required for androgen-stimulated gene expression in prostate cancer. Endocrinology. 2004; 145(6):2941-2949.
10. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM and Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem. 2004; 279(18):19191-19200.
11. Wang L, Lin HK, Hu YC, Xie S, Yang L and Chang C. Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3 beta in prostate cells. J Biol Chem. 2004; 279(31):32444-32452.
12. Schutz SV, Cronauer MV and Rinnab L. Inhibition of glycogen synthase kinase-3beta promotes nuclear export of the androgen receptor through a CRM1-dependent mechanism in prostate cancer cell lines. J Cell Biochem. 2010; 109(6):1192-1200.
13. Yang J, Takahashi Y, Cheng E, Liu J, Terranova PF, Zhao B, Thrasher JB, Wang HG and Li B. GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci. 2010; 123(Pt 6):861-870.
14. Goc A, Al-Husein B, Katsanevas K, Steinbach A, Lou U, Sabbineni H, DeRemer DL and Somanath PR. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget. 2014; 5(3):775-787.
15. Du Q and Geller DA. Cross-Regulation Between Wnt and NF-kappaB Signaling Pathways. For Immunopathol Dis Therap. 2010; 1(3):155-181.
16. Doble BW, Patel S, Wood GA, Kockeritz LK and Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007; 12(6):957-971.
17. Cho J, Rameshwar P and Sadoshima J. Distinct roles of glycogen synthase kinase (GSK)-3alpha and GSK-3beta in mediating cardiomyocyte differentiation in murine bone marrow-derived mesenchymal stem cells. J Biol Chem. 2009; 284(52):36647-36658.
18. Liang MH and Chuang DM. Differential roles of glycogen synthase kinase-3 isoforms in the regulation of transcriptional activation. J Biol Chem. 2006; 281(41):30479-30484.
19. Graham JR, Tullai JW and Cooper GM. GSK-3 represses growth factor-inducible genes by inhibiting NF-kappaB in quiescent cells. J Biol Chem. 2009; 285(7):4472-4480.
20. Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K and Kracht M. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem. 2004; 279(48):49571-49574.
21. Demarchi F, Bertoli C, Sandy P and Schneider C. Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability. J Biol Chem. 2003; 278(41):39583-39590.
22. Park SH, Park-Min KH, Chen J, Hu X and Ivashkiv LB. Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat Immunol. 12(7):607-615.
23. Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S and Maggirwar SB. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol. 2003; 23(13):4649-4662.
24. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O and Woodgett JR. Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature. 2000; 406(6791):86-90.
25. Steinbrecher KA, Wilson W, 3rd, Cogswell PC and Baldwin AS. Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol. 2005; 25(19):8444-8455.
26. Itoh S, Saito T, Hirata M, Ushita M, Ikeda T, Woodgett JR, Algul H, Schmid RM, Chung UI and Kawaguchi H. GSK-3alpha and GSK-3beta proteins are involved in early stages of chondrocyte differentiation with functional redundancy through RelA protein phosphorylation. J Biol Chem. 2012; 287(35):29227-29236.
27. Li H, Xu LL, Masuda K, Raymundo E, McLeod DG, Dobi A and Srivastava S. A feedback loop between the androgen receptor and a NEDD4-binding protein, PMEPA1, in prostate cancer cells. J Biol Chem. 2008; 283(43):28988-28995.
28. Kroon J, In't Veld LS, Buijs JT, Cheung H, van der Horst G and van der Pluijm G. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth. Oncotarget. 2014; [advance online publication].
29. Liu T, Xu F, Du X, Lai D, Liu T, Zhao Y, Huang Q, Jiang L, Huang W, Cheng W and Liu Z. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1. Molecular and cellular biochemistry. 2010; 340(1-2):265-273.
30. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR and Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007; 408(3):297-315.
31. Altuwaijri S, Lin HK, Chuang KH, Lin WJ, Yeh S, Hanchett LA, Rahman MM, Kang HY, Tsai MY, Zhang Y, Yang L and Chang C. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells. Cancer Res. 2003; 63(21):7106-7112.
32. Nelius T, Filleur S, Yemelyanov A, Budunova I, Shroff E, Mirochnik Y, Aurora A, Veliceasa D, Xiao W, Wang Z and Volpert OV. Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer. 2007; 121(5):999-1008.
33. Shih VF, Tsui R, Caldwell A and Hoffmann A. A single NFkappaB system for both canonical and non-canonical signaling. Cell Res. 2011; 21(1):86-102.
34. Mayo MW, Madrid LV, Westerheide SD, Jones DR, Yuan XJ, Baldwin AS, Jr, and Whang YE. PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem. 2002; 277(13):11116-11125.
35. Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES and Lewis BA. Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood. 2012; 120(18):3756-3763.
36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.
37. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M and Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol. 2004; 22(14):2790-2799.
38. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G and Golub TR. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006; 10(4):321-330.
39. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR and Aster JC. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005; 106(4):1392-1399.
40. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE and Wilson M. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 18(1):11-22.
41. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L and Anstett M. The mutational landscape of lethal castration-resistant prostate cancer. Nature. 2012; 487(7406):239-243.
42. Zamek-Gliszczynski MJ, Abraham TL, Alberts JJ, Kulanthaivel P, Jackson KA, Chow KH, McCann DJ, Hu H, Anderson S, Furr NA, Barbuch RJ and Cassidy KC. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure. Drug Metab Dispos. 2013; 41(4):714-726.
43. Bachelder RE, Yoon SO, Franci C, de Herreros AG and Mercurio AM. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription: implications for the epithelial-mesenchymal transition. J Cell Biol. 2005; 168(1):29-33.
44. Neumann M, Klar S, Wilisch-Neumann A, Hollenbach E, Kavuri S, Leverkus M, Kandolf R, Brunner-Weinzierl MC and Klingel K. Glycogen synthase kinase-3beta is a crucial mediator of signal-induced RelB degradation. Oncogene. 2011; 30(21):2485-2492.
45. Lessard L, Begin LR, Gleave ME, Mes-Masson AM and Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer. 2005; 93(9):1019-1023.
46. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A and St Clair WH. RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res. 2009; 69(8):3267-3271.
47. Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, Scher HI and Gerald WL. NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 2009; 175(2):489-499.
48. Nadiminty N, Lou W, Sun M, Chen J, Yue J, Kung HJ, Evans CP, Zhou Q and Gao AC. Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells. Cancer Res. 2010; 70(8):3309-3319.
49. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE and Matusik RJ. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008; 68(16):6762-6769.
50. Ko S, Shi L, Kim S, Song CS and Chatterjee B. Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol. 2008; 22(2):273-286.
51. Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Jr, and Matusik RJ. NF-kappaB gene signature predicts prostate cancer progression. Cancer Res. 2014; 74(10):2763-2772.
52. Tang QL, Xie XB, Wang J, Chen Q, Han AJ, Zou CY, Yin JQ, Liu DW, Liang Y, Zhao ZQ, Yong BC, Zhang RH, Feng QS, Deng WG, Zhu XF and Zhou BP. Glycogen synthase kinase-3beta, NF-kappaB signaling, and tumorigenesis of human osteosarcoma. J Natl Cancer Inst. 2012; 104(10):749-763.
53. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H and Schmidt B. Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3alpha. J Med Chem. 2012; 55(9):4407-4424.
54. Piva M, Domenici G, Iriondo O, Rabano M, Simoes BM, Comaills V, Barredo I, Lopez-Ruiz JA, Zabalza I, Kypta R and Vivanco M. Sox2 promotes tamoxifen resistance in breast cancer cells. EMBO molecular medicine. 2014; 6(1):66-79.
55. Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, Waxman J and Kypta R. Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-beta/Smad signalling. J Cell Sci. 2013; 126(Pt 8):1858-1867.
56. Alfonso RJ, Gorrono-Etxebarria I, Rabano M, Vivanco MD and Kypta R. Dickkopf-3 alters the morphological response to retinoic acid during neuronal differentiation of human embryonal carcinoma cells. Developmental neurobiology. 2014
57. Bookout AL and Mangelsdorf DJ. Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways. Nucl Recept Signal. 2003; 1:e012.
58. Giannini AL, Vivanco M and Kypta RM. alpha-catenin inhibits beta-catenin signaling by preventing formation of a beta-catenin*T-cell factor*DNA complex. J Biol Chem. 2000; 275(29):21883-21888.
59. Campa VM and Kypta RM. Issues associated with the use of phosphospecific antibodies to localise active and inactive pools of GSK-3 in cells. Biol Direct. 2011; 6:4.
60. Castano Z, Gordon-Weeks PR and Kypta RM. The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth. J Neurochem. 2010; 113(1):117-130.
61. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C and Pandolfi PP. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature. 2005; 436(7051):725-730.
62. Schmitz ML and Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. Embo J. 1991; 10(12):3805-3817.
63. Veeman MT, Slusarski DC, Kaykas A, Louie SH and Moon RT. Zebrafish prickle, a modulator of noncanonical Wnt/Fz signaling, regulates gastrulation movements. Curr Biol. 2003; 13(8):680-685.